This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Evaluation of Diabetes Care at Austrian GPs (DCA09)

This study has been terminated.
Bristol-Myers Squibb
Information provided by:
AstraZeneca Identifier:
First received: September 17, 2009
Last updated: August 16, 2010
Last verified: August 2010

This registery should show the medical care of patient with Type 2 Diabetes (T2D) at GP-offices. Furthermore data of co morbidities and risk factors should be evaluated. Objectives of this NIS (cross-sectional study) are:

  • To evaluate which characteristics or co-morbidities are being existent for patient with T2D at GP level,
  • To evaluate representative profile of patient with T2D in Austria,
  • To evaluate which medical therapies are used.

Type 2 Diabetes

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Diabetes Care Austria 2009

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Evaluate characteristics or co morbidities being existent for patient with T2D at GP [ Time Frame: Once per patient ]

Enrollment: 1513
Study Start Date: October 2009
Study Completion Date: January 2010
Primary Completion Date: January 2010 (Final data collection date for primary outcome measure)
Patients with type 2 diabetes


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Inclusion Criteria:

  • Diabetes mellitus type II

Exclusion Criteria:

  • Diabetes mellitus type I
  • Gestation diabetes
  • Induced diabetes
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00979394

Sponsors and Collaborators
Bristol-Myers Squibb
Study Chair: Bernhard Ludvig General Hospital Vienna
Study Chair: Guntram Schernthaner Krankenanstalt Rudolfsstiftung
  More Information

Responsible Party: MC MD, AstraZeneca Identifier: NCT00979394     History of Changes
Other Study ID Numbers: NIS-CAT-DUM-2009/1
Study First Received: September 17, 2009
Last Updated: August 16, 2010

Keywords provided by AstraZeneca:
Diabetes Care at GPs in Austria
Characteristic of diabetes patients at GPs in Austria

Additional relevant MeSH terms:
Diabetes Mellitus
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases processed this record on September 21, 2017